Nuformix plc (LON:NFX – Get Free Report) shares hit a new 52-week low on Monday . The company traded as low as GBX 0.05 ($0.00) and last traded at GBX 0.06 ($0.00), with a volume of 49190609 shares trading hands. The stock had previously closed at GBX 0.06 ($0.00).
Nuformix Stock Performance
The business’s 50-day moving average price is GBX 0.17 and its 200-day moving average price is GBX 0.18. The company has a debt-to-equity ratio of 1.17, a quick ratio of 3.35 and a current ratio of 1.12. The stock has a market cap of £499,779.10, a P/E ratio of -1.63 and a beta of 1.22.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Featured Stories
- Five stocks we like better than Nuformix
- Stock Market Upgrades: What Are They?
- The Average 401k Balance by Age Explained
- How to Capture the Benefits of Dividend Increases
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- How to Start Investing in Real Estate
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
